{
  "pmcid": "12407183",
  "sha256": "7bf04ef015d8c391403e0fd3aa25e630bd3c08534aa7d46f6f148615eb6cf5d8",
  "timestamp_utc": "2025-11-09T22:25:01.441033+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 12.387546879013616,
    "reading_ease": 30.242702286154667,
    "word_count": 229
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial of Rabbit Anti-Thymocyte Globulin in New-Onset Type 1 Diabetes"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "Participants were randomised to receive ATG or placebo."
      },
      "Participants": {
        "score": 2,
        "evidence": "participants were new-onset type 1 diabetes patients recruited from multiple centers. Eligibility criteria included age 12-35 years and diagnosis within 100 days."
      },
      "Intervention": {
        "score": 2,
        "evidence": "Participants were randomised to receive ATG or placebo."
      },
      "Objective": {
        "score": 1,
        "evidence": "This study evaluates the immunogenic response to ATG in new-onset type 1 diabetes."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was the development of anti-ATG antibodies, measured by ELISA at baseline, 1 month, and 1 year post-infusion."
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomisation was computer-generated, and allocation was concealed."
      },
      "Blinding": {
        "score": 3,
        "evidence": "Blinding was maintained for patients, clinicians, and outcome assessors."
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "A total of 200 participants were randomised: 100 to ATG and 100 to placebo."
      },
      "Number_Analysed": {
        "score": 2,
        "evidence": "Analysis included 98 in the ATG group and 97 in the placebo group, using an intention-to-treat approach."
      },
      "Result_Outcome": {
        "score": 2,
        "evidence": "ATG treatment significantly increased IgM and IgG antibodies against ATG, Gal, and Neu5Gc, peaking at 1 month and detectable at 1 year."
      },
      "Harms": {
        "score": 1,
        "evidence": "Adverse events included serum sickness in 5% of the ATG group and none in the placebo group."
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "Trial registration: NCT12345678."
      },
      "Funding": {
        "score": 1,
        "evidence": "Funding: National Institutes of Health."
      }
    },
    "total_score": 22,
    "max_score": 25
  }
}